10 proposals for the attention of candidates for the Presidency of the French Republic
Paris, 13 March 2012. At a time when employment and industry renewal in France are major subjects for public debate, and in a period of unprecedented economic turmoil, the G5 healthcare association is taking the opportunity to demonstrate the major contribution to the country made by health industries in terms of employment, competitiveness, independence in health provision and innovation.
Based on a thorough analysis of the situation, published in the form of a White Paper, the G5 healthcare association has set out 10 key proposals to respond to the challenges faced by the healthcare industry in France. The objective is two-fold: to offer a better response to healthcare needs in France, and to strengthen the country’s position in a highly competitive international healthcare sector.
For the G5 association, the route to success lies in an immediate dual initiative:
- developing a dynamic healthcare industry, operating within a fast-changing medical environment
- renewing dialogue with public authorities for the benefit of the French and for employment
The G5 has laid out 10 strategies for success:
Recognizing the social and economic utility of the healthcare industry:
1. Restoring a joint strategic vision and a fruitful dialogue between public authorities and healthcare industries, in order to renew political and administrative governance
2. Respecting innovation, taking into account effective industrial approaches to the implementation of regulation and price-setting policies, and measuring the impact of reforms on the healthcare industry, with the implementation of impact studies on government decisions and their consequences for the healthcare industry
3. Structuring a sustainable healthcare sector to help renew French industry, supporting the French industry strategic committee [Comité Stratégique de Filières, CSF], in particular by adopting the notion of social and environmental service contribution (Service Sociétal et Environnemenal Rendu, SSER), supporting the emergence of new sectors with significant industrial potential, and involving all players to respond to major public healthcare challenges
4. Encouraging employment and training in healthcare industry specialty fields through the creation of a one-stop approach, matching supply and demand of skills, mapping employment and training needs, sharing public research platforms and promoting a national plan for mixed training and career paths
Renewing control of access to the market for new products:
5. Restoring access to the market and encouraging innovation, specifically by establishing objective, sustainable price-setting criteria, broadening the concept of Improved medical benefits delivered [Amélioration du Service Médical Rendu, ASMR], assessing drugs throughout their lifecycle and enabling the registration of break-through innovations earlier.
6. Setting up an inter-ministerial arbitration authority, at the highest level of government, responsible for determining the major financial, health, industrial and research balancing factors, while also preserving the Healthcare Industries Strategic Committee (Conseil Stratégique des Industries de Santé, CSIS)
Developing a coherent research policy:
7. Maintaining the research tax credit, and developing public/private partnerships in particular by positioning the Health industries research and innovation agency (Agence de Recherche et d’Innovation des Industries de Santé, ARIIS), the National research agency (Agence Nationale de Recherche, ANR) and the Life science and health alliance (Alliance pour les Sciences de la Vie et de la Santé, AVIESAN) as partnership steering groups and developing clusters.
8. Enabling health industries to maintain high quality R&D, through the development of policies to support public and private R&D, in particular through national action programs (such as for cancer)
Promoting France at the international level:
9. Encouraging the emergence of national champions for medical devices and multi-technology solutions by improving funding for new, break-through products. France should lead the definition of standards and regulations that will help launch new paradigms.
10. Support international development of healthcare businesses, to provide true healthcare diplomacy, creating an export credit for healthcare SMEs, developing strategic partnerships with universities around the world and deploying a diplomatic service in healthcare aimed at areas of French influence
About G5 health (http://www.g5.asso.fr )
G5 health, the voice for the French health industry, is a forum for the leaders of the major health and bio-sciences companies in France (bioMérieux, Ipsen, LFB, Pierre Fabre, Sanofi). These groups have chosen France as the base for their international development, and they make R&D their priority. The members of the G5 health share 5 ambitions: to gain recognition for the crucial contribution of the life sciences in public health in France, to help to restore France’s competitive position, to commit strongly to increase excellence in French bio-medical research, to improve patients’ access to health solutions and to support the biotechnology and new technology sectors.
Marie-Madeleine de Montera
+33 (0)6 03 45 87 83 email@example.comRevenir à la liste des articles